Pfizer Q4 Adjusted EPS $0.10 Beats $(0.22) Estimate, Sales $14.25B Beat $14.21B Estimate
Portfolio Pulse from Benzinga Newsdesk
Pfizer Inc. (NYSE:PFE) reported Q4 earnings of $0.10 per share, surpassing the analyst consensus estimate of $(0.22) by 145.45%. However, this represents a 91.23% decrease from the $1.14 per share earned in the same quarter last year. Quarterly sales were $14.25 billion, slightly above the consensus estimate of $14.21 billion, but marked a 41.34% decrease from the $24.29 billion reported in the same period last year.
January 30, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's Q4 earnings exceeded expectations, but showed significant declines from the previous year in both EPS and sales.
While Pfizer's earnings and sales beat estimates, the substantial year-over-year declines in both metrics may concern investors. The mixed results could lead to neutral short-term stock price movement as the market digests both the positive surprise in earnings and the negative trend in year-over-year performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100